scholarly journals Quantitative R1 in the locus coeruleus in Alzheimer’s disease dementia

2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Deepali M. Bhalla ◽  
Akshay Kohli ◽  
Matthew Betts ◽  
Mary‐Elizabeth Pasquesi ◽  
Veena A. Nair ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Locus Coeruleus ◽  
Alzheimer’S Disease Dementia

scholarly journals Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF Aβ levels

2019 ◽  
Vol 11 (1) ◽  
pp. 281-285 ◽  
Author(s):  
Matthew J. Betts ◽  
Arturo Cardenas‐Blanco ◽  
Martin Kanowski ◽  
Annika Spottke ◽  
Stefan J. Teipel ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Locus Coeruleus ◽  
Mri Contrast ◽  
Alzheimer’S Disease Dementia

Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia

2018 ◽  
Vol 15 (4) ◽  
pp. 386-398 ◽  
Author(s):  
Fabricio Ferreira de Oliveira ◽  
Elizabeth Suchi Chen ◽  
Marilia Cardoso Smith ◽  
Paulo Henrique Ferreira Bertolucci
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Angiotensin Converting Enzyme ◽  
Cognitive Decline ◽  
Enzyme Inhibitors ◽  
Late Onset ◽  
Amyloid Β ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Alzheimer’S Disease Dementia

Background: While the angiotensin-converting enzyme degrades amyloid-β, angiotensinconverting enzyme inhibitors (ACEis) may slow cognitive decline by way of cholinergic effects, by increasing brain substance P and boosting the activity of neprilysin, and by modulating glucose homeostasis and augmenting the secretion of adipokines to enhance insulin sensitivity in patients with Alzheimer’s disease dementia (AD). We aimed to investigate whether ACE gene polymorphisms rs1800764 and rs4291 are associated with cognitive and functional change in patients with AD, while also taking APOE haplotypes and anti-hypertensive treatment with ACEis into account for stratification. Methods: Consecutive late-onset AD patients were screened with cognitive tests, while their caregivers were queried for functional and caregiver burden scores. Prospective pharmacogenetic correlations were estimated for one year, considering APOE and ACE genotypes and haplotypes, and treatment with ACEis. Results: For 193 patients, minor allele frequencies were 0.497 for rs1800764 – C (44.6% heterozygotes) and 0.345 for rs4291 – T (38.9% heterozygotes), both in Hardy-Weinberg equilibrium. Almost 94% of all patients used cholinesterase inhibitors, while 155 (80.3%) had arterial hypertension, and 124 used ACEis. No functional impacts were found regarding any genotypes or pharmacological treatment. Either for carriers of ACE haplotypes that included rs1800764 – T and rs4291 – A, or for APOE4- carriers of rs1800764 – T or rs4291 – T, ACEis slowed cognitive decline independently of blood pressure variations. APOE4+ carriers were not responsive to treatment with ACEis. Conclusion: ACEis may slow cognitive decline for patients with AD, more remarkably for APOE4- carriers of specific ACE genotypes.

scholarly journals Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

2021 ◽  
Author(s):  
Sebastian Palmqvist ◽  
◽  
Pontus Tideman ◽  
Nicholas Cullen ◽  
Henrik Zetterberg ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Alzheimer’S Disease Dementia

scholarly journals TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing

2016 ◽  
Vol 27 (4) ◽  
pp. 472-479 ◽  
Author(s):  
Kirsty E. McAleese ◽  
Lauren Walker ◽  
Daniel Erskine ◽  
Alan J. Thomas ◽  
Ian G. McKeith ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Alzheimer’S Disease Dementia
Sign in / Sign up

Export Citation Format

Share Document